TY - JOUR
T1 - Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro
AU - Ogawa, Norio
AU - Tanaka, Ken ichi
AU - Asanuma, Masato
AU - Kawai, Motoko
AU - Masumizu, Toshiki
AU - Kohno, Masahiro
AU - Mori, Akitane
N1 - Funding Information:
This study was supported in part by a grant-in-aid for Scientific Research from the Japanese Ministry of Education, Science and Culture, and grants for Research Projects on Aging and Health and for the Research Committee of CNS Degenerative Diseases from the Japanese Ministry of Health and Welfare. The authors would like to thank Professor Edith G. McGeer, Kinsmen Laboratory of Neurological Research, University of British Columbia, Canada for criticism of the manuscript. We would like to thank Miss Hiroko Danjo for her technical support in performing the experiments.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1994/9/19
Y1 - 1994/9/19
N2 - Pretreatment with bromocriptine (5 mg/kg, i.p., 7 days) completely protected against the decrease in mouse striatal dopamine and its metabolites induced by intraventricular injection of 6-hydroxydopamine after intraperitoneal administration of desipramine, but similar pretreatment with l-DOPA/carbidopa (75/7.5 mg/kg, i.p., 7 days) showed only partial protective effect. Furthermore, in an in vitro system that generated ·OH from FeSO4-H2O2, bromocriptine dose-dependently reduced the number of ·OH radicals. These findings indicate that bromocriptine has a neuroprotective effect against neurotoxins such as 6-hydroxydopamine, probably due, in part, to its hydroxyl radical scavenging activity and inhibiting effect on dopamine turnover rate. This suggests that early introduction of bromocriptine in the therapy of Parkinson's disease may be superior to treatment with l-DOPA alone.
AB - Pretreatment with bromocriptine (5 mg/kg, i.p., 7 days) completely protected against the decrease in mouse striatal dopamine and its metabolites induced by intraventricular injection of 6-hydroxydopamine after intraperitoneal administration of desipramine, but similar pretreatment with l-DOPA/carbidopa (75/7.5 mg/kg, i.p., 7 days) showed only partial protective effect. Furthermore, in an in vitro system that generated ·OH from FeSO4-H2O2, bromocriptine dose-dependently reduced the number of ·OH radicals. These findings indicate that bromocriptine has a neuroprotective effect against neurotoxins such as 6-hydroxydopamine, probably due, in part, to its hydroxyl radical scavenging activity and inhibiting effect on dopamine turnover rate. This suggests that early introduction of bromocriptine in the therapy of Parkinson's disease may be superior to treatment with l-DOPA alone.
KW - 6-Hydroxydopamine
KW - Bromocriptine
KW - Free radical
KW - Hydroxyl radical
KW - Neuroprotection
KW - Parkinson's disease
KW - l-DOPA
UR - http://www.scopus.com/inward/record.url?scp=0028068121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028068121&partnerID=8YFLogxK
U2 - 10.1016/0006-8993(94)90969-5
DO - 10.1016/0006-8993(94)90969-5
M3 - Article
C2 - 7820619
AN - SCOPUS:0028068121
SN - 0006-8993
VL - 657
SP - 207
EP - 213
JO - Molecular Brain Research
JF - Molecular Brain Research
IS - 1-2
ER -